HTR2A (5-hydroxytryptamine receptor 2A) variants and mutations
HTR2A (also known as 5-hydroxytryptamine receptor 2A) is a human protein-coding gene encoding a 5-hydroxytryptamine receptor 2A protein. Its activation by serotonin engages Gq signaling in cortical, vascular, and other tissues and influences perception, mood, cognition, and smooth-muscle responses. It is a major target of many antipsychotic drugs and psychedelic compounds, while common genetic effects on behavior are generally modest. This analysis covers 807 HTR2A variants and mutations. Of these, 96% have computational variant effect predictions. Disease context includes major depressive disorder, schizophrenia, and autism. Example HTR2A variants include D2N, I3F, and L4R.
Variant analysis overview
- Gene: HTR2A
- Protein: 5-hydroxytryptamine receptor 2A
- UniProt accession: P28223
- Organism: Homo sapiens
- Variants analyzed: 807
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 451 unspecified-consequence records; 155 synonymous variants; 172 missense variants; 17 frameshift variants; 8 stop-gained variants; 1 in-frame insertions; 1 in-frame deletions; 1 splice-region variants; 1 stop retained variant
- Prediction scores: 773 variants have prediction scores (96% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: major depressive disorder, schizophrenia, autism, psychotic disorder, bipolar disorder, depressive disorder, bipolar I disorder, Agitation, schizoaffective disorder, aggressive behavior, Tourette syndrome, insomnia.
Protein structure and variant hotspots
- Protein features: 7 transmembrane segments; 2 binding sites; 6 post-translational modification sites.
- Structural context: 275 variants have structural context.
- PTM context: 7 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable HTR2A variants
Examples include D2N, I3F, L4R, C5Y, E6G, E6K, N8K, S10C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- D2N (p.Asp2Asn), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66326, TOPMed rs1951099887, MetaLR 0.08, MetaSVM -1.05, Variant assessed as somatic; moderate impact.
- I3F (p.Ile3Phe), rs532924268, ClinGen CA249262512, ClinVar RCV004271312, TOPMed rs532924268, REVEL 0.06, MetaLR 0.09, Uncertain significance, not specified
- L4R (p.Leu4Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- C5Y (p.Cys5Tyr), TOPMed rs1307418905, gnomAD rs1307418905, REVEL 0.04, MetaLR 0.07
- E6G (p.Glu6Gly), gnomAD rs1418879482, REVEL 0.11, MetaLR 0.10
- E6K (p.Glu6Lys), cosmic curated COSV66328, Ensembl rs748483027, REVEL 0.06, MetaLR 0.08
- N8K (p.Asn8Lys), NCI-TCGA TCGA novel, MetaLR 0.06, MetaSVM -1.06, Variant assessed as somatic; high impact.
- S10C (p.Ser10Cys), TOPMed rs1870033849, gnomAD rs1870033849
- S10Y (p.Ser10Tyr), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, TOPMed rs1870033849, gnomAD rs1870033849, MetaLR 0.11, MetaSVM -0.93, Variant assessed as somatic; moderate impact.
- L11F (p.Leu11Phe), Ensembl rs1951099502
- S12N (p.Ser12Asn), cosmic curated COSV10593, 1000Genomes rs545813583, ExAC rs545813583, TOPMed rs545813583, REVEL 0.12, MetaLR 0.05
- S13* (p.Ser13Ter), gnomAD rs1266978961, CADD 35.00
- T14A (p.Thr14Ala), ExAC rs747855847, gnomAD rs747855847, REVEL 0.02, MetaLR 0.09
- T14I (p.Thr14Ile), ExAC rs778929461, TOPMed rs778929461, gnomAD rs778929461, REVEL 0.10, MetaLR 0.07
- T15M (p.Thr15Met), ExAC rs754812239, gnomAD rs754812239, REVEL 0.07, MetaLR 0.08
- T15S (p.Thr15Ser), NCI-TCGA TCGA novel, MetaLR 0.08, MetaSVM -1.02, Variant assessed as somatic; moderate impact.
- N16S (p.Asn16Ser), TOPMed rs1757675998, REVEL 0.11, MetaLR 0.08
- S17T (p.Ser17Thr), ExAC rs765936117, gnomAD rs765936117, REVEL 0.08, MetaLR 0.07
- M19I (p.Met19Ile), ExAC rs750120780, TOPMed rs750120780, gnomAD rs750120780, REVEL 0.07, MetaLR 0.04
- M19K (p.Met19Lys), TOPMed rs1052540084, REVEL 0.04, MetaLR 0.09
- M19T (p.Met19Thr), TOPMed rs1052540084, REVEL 0.05, MetaLR 0.09
- L21I (p.Leu21Ile), 1000Genomes rs185040200, ExAC rs185040200, REVEL 0.11, MetaLR 0.06
- D23G (p.Asp23Gly), ExAC rs762264146, gnomAD rs762264146, REVEL 0.06, MetaLR 0.05
- D24N (p.Asp24Asn), ExAC rs774523543, gnomAD rs774523543, REVEL 0.08, MetaLR 0.13
- T25I (p.Thr25Ile), cosmic curated COSV66328, 1000Genomes rs1805055, ESP rs1805055, ExAC rs1805055, REVEL 0.02, MetaLR 0.08
- T25N (p.Thr25Asn), rs1805055, cosmic curated COSV66327, UniProt VAR 003448, 1000Genomes rs1805055, REVEL 0.12, MetaLR 0.03
- T25S (p.Thr25Ser), 1000Genomes rs1805055, ESP rs1805055, ExAC rs1805055, TOPMed rs1805055, REVEL 0.10, MetaLR 0.06
- R26K (p.Arg26Lys), gnomAD rs1295715779, REVEL 0.08, MetaLR 0.09
- S29G (p.Ser29Gly), ExAC rs770043192, REVEL 0.09, MetaLR 0.07
- S29T (p.Ser29Thr), rs1332655388, ClinGen CA388154889, ClinVar RCV004404852, TOPMed rs1332655388, REVEL 0.04, MetaLR 0.07, Uncertain significance, not specified
- N30Y (p.Asn30Tyr), ExAC rs745909918, TOPMed rs745909918, gnomAD rs745909918, REVEL 0.07, MetaLR 0.11
- D31E (p.Asp31Glu), TOPMed rs1951098415, REVEL 0.05, MetaLR 0.08
- D31N (p.Asp31Asn), ExAC rs777023991, TOPMed rs777023991, gnomAD rs777023991, REVEL 0.13, MetaLR 0.10
- D31Y (p.Asp31Tyr), ExAC rs777023991, TOPMed rs777023991, gnomAD rs777023991, REVEL 0.08, MetaLR 0.10, Uncertain significance, not specified
- F32L (p.Phe32Leu), TOPMed rs1414598346, gnomAD rs1414598346, REVEL 0.17, MetaLR 0.06
- S34=, rs6313, ClinVar RCV000615738, ClinVar RCV001836646, Benign
- S34C (p.Ser34Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S34Y (p.Ser34Tyr), gnomAD rs1175892869, REVEL 0.08, MetaLR 0.11
- G35A (p.Gly35Ala), gnomAD rs1246186555, REVEL 0.07, MetaLR 0.10
- G35R (p.Gly35Arg), cosmic curated COSV10749, 1000Genomes rs1046592807, TOPMed rs1046592807, gnomAD rs1046592807, REVEL 0.07, MetaLR 0.07
- E36K (p.Glu36Lys), Ensembl rs868475357, REVEL 0.10, MetaLR 0.09
- A37V (p.Ala37Val), TOPMed rs1175309453, gnomAD rs1175309453, REVEL 0.17, MetaLR 0.06
- N38D (p.Asn38Asp), Ensembl rs1951097896, MetaLR 0.20, MetaSVM -0.84
- N38K (p.Asn38Lys), ESP rs375024989, ExAC rs375024989, TOPMed rs375024989, gnomAD rs375024989, REVEL 0.14, MetaLR 0.20
- T39A (p.Thr39Ala), TOPMed rs1045024958
- T39I (p.Thr39Ile), Ensembl rs1951097639, REVEL 0.11, MetaLR 0.08
- S40C (p.Ser40Cys), ExAC rs768489549, REVEL 0.29, MetaLR 0.27
- S40T (p.Ser40Thr), ExAC rs778501828, gnomAD rs778501828, REVEL 0.16, MetaLR 0.21
- D41G (p.Asp41Gly), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10109, MetaLR 0.06, MetaSVM -1.05, Variant assessed as somatic; moderate impact.
- F43I (p.Phe43Ile), TOPMed rs1459537012, gnomAD rs1459537012, REVEL 0.06, MetaLR 0.04, Uncertain significance, not specified
- F43V (p.Phe43Val), rs1459537012, ClinGen CA388154799, ClinVar RCV004320592, TOPMed rs1459537012, REVEL 0.05, MetaLR 0.04, Uncertain significance, not specified
- W45L (p.Trp45Leu), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, MetaLR 0.05, MetaSVM -1.08, Variant assessed as somatic; moderate impact.
- T46A (p.Thr46Ala), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, Variant assessed as somatic; moderate impact.
- T46I (p.Thr46Ile), ExAC rs749275506, TOPMed rs749275506, gnomAD rs749275506, REVEL 0.28, MetaLR 0.09
- D48H (p.Asp48His), ExAC rs755654778, TOPMed rs755654778, gnomAD rs755654778
- D48N (p.Asp48Asn), ExAC rs755654778, TOPMed rs755654778, gnomAD rs755654778, REVEL 0.07, MetaLR 0.06
- S49F (p.Ser49Phe), Ensembl rs1566322981, MetaLR 0.06, MetaSVM -1.03
- R52* (p.Arg52Ter), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66326, gnomAD rs1222375103, CADD 36.00, Variant assessed as somatic; high impact.
- R52G (p.Arg52Gly), rs1222375103, NCI-TCGA Cosmic COSV6632, gnomAD rs1222375103, REVEL 0.08, MetaLR 0.04, Variant assessed as somatic; moderate impact.
- R52L (p.Arg52Leu), 1000Genomes rs572796124, ExAC rs572796124, TOPMed rs572796124, gnomAD rs572796124, MetaLR 0.04, MetaSVM -1.03
- R52Q (p.Arg52Gln), cosmic curated COSV66327, 1000Genomes rs572796124, ExAC rs572796124, TOPMed rs572796124, REVEL 0.10, MetaLR 0.04
- C57F (p.Cys57Phe), TOPMed rs896284675, gnomAD rs896284675, REVEL 0.22, MetaLR 0.06
- E58K (p.Glu58Lys), TOPMed rs1056712633, gnomAD rs1056712633, REVEL 0.13, MetaLR 0.06
- G59A (p.Gly59Ala), gnomAD rs1403980207, REVEL 0.06, MetaLR 0.08
- C60* (p.Cys60Ter), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, Variant assessed as somatic; high impact.
- C60F (p.Cys60Phe), rs763386955, ExAC rs763386955, gnomAD rs763386955, REVEL 0.06, MetaLR 0.04, Variant assessed as somatic; moderate impact.
- C60Y (p.Cys60Tyr), ExAC rs763386955, gnomAD rs763386955, MetaLR 0.03, MetaSVM -1.02
- L61F (p.Leu61Phe), NCI-TCGA TCGA novel, REVEL 0.03, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- L61V (p.Leu61Val), Ensembl rs1593447844
- P63L (p.Pro63Leu), rs1157228569, NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, TOPMed rs1157228569, REVEL 0.18, MetaLR 0.06, Variant assessed as somatic; moderate impact.
- S64A (p.Ser64Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S64L (p.Ser64Leu), cosmic curated COSV10654, Ensembl rs779934468, REVEL 0.06, MetaLR 0.04
- S64P (p.Ser64Pro), TOPMed rs1170876344
- L68F (p.Leu68Phe), ExAC rs776790681, gnomAD rs776790681
- L69R (p.Leu69Arg), TOPMed rs1463932215
- H70H (p.His70His), gnomAD 13-46895484-A-G, CADD 12.90
- H70R (p.His70Arg), rs767680355, gnomAD 13-46895485-T-C, CADD 3.92, SIFT 0.09
- H70N (p.His70Asn), gnomAD 13-46895486-G-T, CADD 8.97, SIFT 0.06
- L71V (p.Leu71Val), TOPMed rs1442771238, gnomAD rs1442771238, REVEL 0.04, MetaLR 0.05
- N75K (p.Asn75Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- N75T (p.Asn75Thr), NCI-TCGA TCGA novel, MetaLR 0.07, MetaSVM -1.09, Variant assessed as somatic; high impact.
- W76C (p.Trp76Cys), rs2542239129, ClinGen CA388153837, ClinVar RCV004404850, Uncertain significance, not specified
- W76L (p.Trp76Leu), ExAC rs760868845, gnomAD rs760868845, REVEL 0.43, MetaLR 0.12
- A78V (p.Ala78Val), ExAC rs773466572, gnomAD rs773466572, REVEL 0.35, MetaLR 0.16
- A82A (p.Ala82Ala), rs779991888, gnomAD 13-46895661-G-C, CADD 9.45
- V83I (p.Val83Ile), rs539430264, NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, 1000Genomes rs539430264, REVEL 0.02, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- V84E (p.Val84Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L87V (p.Leu87Val), TOPMed rs1364080876, gnomAD rs1364080876, REVEL 0.06, MetaLR 0.03
- T88P (p.Thr88Pro), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10109, Variant assessed as somatic; moderate impact.
- T88L (p.Thr88Leu), gnomAD 13-46895641-ATAGT, CADD 32.00
- I89V (p.Ile89Val), gnomAD 13-46895642-T-C, REVEL 0.11, MetaLR 0.07
- A90T (p.Ala90Thr), gnomAD 13-46895639-C-T, REVEL 0.09, MetaLR 0.08
- G91R (p.Gly91Arg), gnomAD rs1951095863, REVEL 0.77, MetaLR 0.59
- G91E (p.Gly91Glu), rs1951095820, gnomAD 13-46895634-TC-T, CADD 31.00
- I93T (p.Ile93Thr), ExAC rs745387744, gnomAD rs745387744, REVEL 0.50, MetaLR 0.21
- I93M (p.Ile93Met), gnomAD 13-46895628-T-C, REVEL 0.38, MetaLR 0.20
- L94F (p.Leu94Phe), TOPMed rs1215391625, gnomAD rs1215391625, REVEL 0.74, MetaLR 0.68
- L94L (p.Leu94Leu), rs1381271092, gnomAD 13-46895625-G-A, CADD 6.18
- V95I (p.Val95Ile), rs780635453, NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, ExAC rs780635453, REVEL 0.77, MetaLR 0.79, Variant assessed as somatic; moderate impact.
- I96M (p.Ile96Met), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10109, MetaLR 0.57, MetaSVM 0.17, Variant assessed as somatic; moderate impact.
- M97T (p.Met97Thr), ESP rs370985207, ExAC rs370985207, TOPMed rs370985207, gnomAD rs370985207, REVEL 0.38, MetaLR 0.06
- V99A (p.Val99Ala), TOPMed rs1043732808, gnomAD rs1043732808
- V99L (p.Val99Leu), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10109, Variant assessed as somatic; moderate impact.
- V99V (p.Val99Val), rs1951095465, gnomAD 13-46895610-C-T, CADD 12.10
- S100F (p.Ser100Phe), Ensembl rs868179048, MetaLR 0.17, MetaSVM -1.02
- E102D (p.Glu102Asp), TOPMed rs1453338877, gnomAD rs1453338877, REVEL 0.19, MetaLR 0.06
- E102K (p.Glu102Lys), cosmic curated COSV66326, ExAC rs751219044, gnomAD rs751219044, REVEL 0.39, MetaLR 0.19
- E102A (p.Glu102Ala), rs1465680318, gnomAD 13-46895491-T-G, CADD 22.60, SIFT 0.10
- E102G (p.Glu102Gly), rs1465680318, gnomAD 13-46895491-T-C, CADD 23.00, SIFT 0.06
- E102Q (p.Glu102Gln), gnomAD 13-46895603-C-G, REVEL 0.35, MetaLR 0.18
- E102R (p.Glu102Arg), gnomAD 13-46895604-T-TA, CADD 32.00
- K104K (p.Lys104Lys), gnomAD 13-46895595-C-T, CADD 12.90
- L105L (p.Leu105Leu), rs777450723, gnomAD 13-46895592-C-T, CADD 12.10
- A108S (p.Ala108Ser), TOPMed rs1951095212, MetaLR 0.20, MetaSVM -0.68
- T109P (p.Thr109Pro), TOPMed rs1274149032, gnomAD rs1274149032, REVEL 0.77, MetaLR 0.19
- T109T (p.Thr109Thr), rs758863570, gnomAD 13-46895580-G-A, CADD 13.20
- Y111L (p.Tyr111Leu), rs1160308755, gnomAD 13-46895575-T-TA, CADD 32.00
- Y111H (p.Tyr111His), gnomAD 13-46895576-A-G, REVEL 0.65, MetaLR 0.20
- F112C (p.Phe112Cys), gnomAD 13-46895572-A-C, REVEL 0.91, MetaLR 0.82
- L113M (p.Leu113Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L113R (p.Leu113Arg), gnomAD 13-46895569-A-C, REVEL 0.64, MetaLR 0.51
- M114I (p.Met114Ile), gnomAD 13-46895565-C-T, REVEL 0.42, MetaLR 0.44
- L116L (p.Leu116Leu), rs192268932, gnomAD 13-46895559-A-G, CADD 11.40
- L116P (p.Leu116Pro), gnomAD 13-46895560-A-G, REVEL 0.89, MetaLR 0.92
- L116F (p.Leu116Phe), gnomAD 13-46895561-G-A, REVEL 0.82, MetaLR 0.90
- A117A (p.Ala117Ala), gnomAD 13-46895556-G-A, CADD 13.20
- I118T (p.Ile118Thr), cosmic curated COSV66328, Ensembl rs1951094910, MetaLR 0.10, MetaSVM -1.10
- I118V (p.Ile118Val), ExAC rs765850021, gnomAD rs765850021, REVEL 0.09, MetaLR 0.02
- M121T (p.Met121Thr), gnomAD rs1188200387, REVEL 0.49, MetaLR 0.18
- L122M (p.Leu122Met), ExAC rs760051588, gnomAD rs760051588
- L122L (p.Leu122Leu), rs754360432, gnomAD 13-46895541-C-A, CADD 11.70
- L123M (p.Leu123Met), Ensembl rs1219929320
- L123Q (p.Leu123Gln), gnomAD 13-46895539-A-T, REVEL 0.39, MetaLR 0.18
- F125F (p.Phe125Phe), rs1185553887, gnomAD 13-46895532-G-A, CADD 13.50
- F125L (p.Phe125Leu), gnomAD 13-46895534-A-G, REVEL 0.27, MetaLR 0.02
- L126V (p.Leu126Val), ExAC rs766423438, gnomAD rs766423438, REVEL 0.33, MetaLR 0.43
- V127D (p.Val127Asp), gnomAD rs1219309188, REVEL 0.85, MetaLR 0.72
- V127I (p.Val127Ile), gnomAD rs1264306261, REVEL 0.52, MetaLR 0.58
- V127V (p.Val127Val), gnomAD 13-46895526-G-T, CADD 11.30
- V127L (p.Val127Leu), gnomAD 13-46895528-C-G, REVEL 0.67, MetaLR 0.64
- M128V (p.Met128Val), TOPMed rs1951094539, gnomAD rs1951094539, REVEL 0.49, MetaLR 0.10
- P129A (p.Pro129Ala), TOPMed rs1486595409
- P129S (p.Pro129Ser), TOPMed rs1486595409, MetaLR 0.51, MetaSVM 0.37
- P129P (p.Pro129Pro), rs946733246, gnomAD 13-46895520-G-A, CADD 7.40
- V130M (p.Val130Met), 1000Genomes rs550284437, gnomAD rs550284437, REVEL 0.34, MetaLR 0.42
- S131P (p.Ser131Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S131S (p.Ser131Ser), gnomAD 13-46895514-G-T, CADD 12.30
- M132T (p.Met132Thr), TOPMed rs1476621961, MetaLR 0.01, MetaSVM -1.00
- M132I (p.Met132Ile), gnomAD 13-46895511-C-T, REVEL 0.07, MetaLR 0.03
- L136L (p.Leu136Leu), rs1265334171, gnomAD 13-46895499-C-G, CADD 4.36
- L136M (p.Leu136Met), gnomAD 13-46895501-G-T, REVEL 0.14, MetaLR 0.13
- Y137C (p.Tyr137Cys), NCI-TCGA TCGA novel, TOPMed rs1951094172, MetaLR 0.14, MetaSVM -0.94, Variant assessed as somatic; moderate impact.
- Y137F (p.Tyr137Phe), gnomAD 13-46895497-T-A, REVEL 0.10, MetaLR 0.04
- G138R (p.Gly138Arg), gnomAD rs1246174393, REVEL 0.14, MetaLR 0.13
- G138V (p.Gly138Val), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10109, SIFT 0.00, Variant assessed as somatic; moderate impact.
- G138G (p.Gly138Gly), gnomAD 13-46892589-C-A, CADD 7.93
- G138E (p.Gly138Glu), gnomAD 13-46892590-C-T, REVEL 0.16, MetaLR 0.36
- Y139C (p.Tyr139Cys), TOPMed rs1324037908, gnomAD rs1324037908, REVEL 0.51, MetaLR 0.55
- R140Q (p.Arg140Gln), rs754348347, ClinGen CA6977651, ClinVar RCV004090527, ExAC rs754348347, REVEL 0.10, MetaLR 0.15, Uncertain significance, not specified
- R140W (p.Arg140Trp), cosmic curated COSV10891, TOPMed rs962495795, gnomAD rs962495795, REVEL 0.43, MetaLR 0.41
- R140R (p.Arg140Arg), rs962495795, gnomAD 13-46892585-G-T, CADD 12.10
- R140G (p.Arg140Gly), gnomAD 13-46892585-G-C, REVEL 0.07, MetaLR 0.17
- W141* (p.Trp141Ter), TOPMed rs1951062583
- W141R (p.Trp141Arg), gnomAD rs1330614688, NCI-TCGA TCGA novel, REVEL 0.83, MetaLR 0.81, Variant assessed as somatic; moderate impact.
- W141C (p.Trp141Cys), rs773341404, gnomAD 13-46895487-C-A, CADD 13.10, SIFT 0.00
- P144L (p.Pro144Leu), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, Ensembl rs2138255797, REVEL 0.55, MetaLR 0.29, Variant assessed as somatic; moderate impact.
- P144S (p.Pro144Ser), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66327, MetaLR 0.21, MetaSVM -0.77, Variant assessed as somatic; moderate impact.
- P144P (p.Pro144Pro), rs756173983, gnomAD 13-46892571-C-T, CADD 1.42
- P144Q (p.Pro144Gln), gnomAD 13-46892572-G-T, REVEL 0.49, MetaLR 0.27
- P144T (p.Pro144Thr), gnomAD 13-46892573-G-T, REVEL 0.56, MetaLR 0.26
- K146Q (p.Lys146Gln), gnomAD rs1425158265, REVEL 0.18, MetaLR 0.14
- K146T (p.Lys146Thr), gnomAD 13-46892566-T-G, REVEL 0.19, MetaLR 0.14
- L147F (p.Leu147Phe), gnomAD 13-46892564-G-A, REVEL 0.16, MetaLR 0.12
- C148S (p.Cys148Ser), gnomAD 13-46892560-C-G, REVEL 0.67, MetaLR 0.68
- A149T (p.Ala149Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V150A (p.Val150Ala), gnomAD rs1453149357, REVEL 0.18, MetaLR 0.08
- V150L (p.Val150Leu), gnomAD 13-46892555-C-G, REVEL 0.02, MetaLR 0.06
- V150I (p.Val150Ile), gnomAD 13-46892555-C-T, REVEL 0.02, MetaLR 0.03
- W151* (p.Trp151Ter), NCI-TCGA Cosmic COSV6632, cosmic curated COSV66326, Variant assessed as somatic; high impact.
- W151R (p.Trp151Arg), TOPMed rs1951062407, REVEL 0.72, MetaLR 0.32
Public HTR2A analysis runs
- HTR2A analysis run — HTR2A (807 variants) — completed 2026-08-19